[Adverse neurotoxic reactions of chemotherapy for tuberculosis and their treatment].
A hundred and sixty-five first detected patients with pulmonary tuberculosis, receiving routine chemotherapy regimens were followed up for 4 months. Neurotoxic reactions of the central and peripheral nervous systems, which required isoniasid discontinuation, were developed in 13.3 and 11.5% of the patients, respectively. Therapy for neurotoxic reactions used cortexin in the study group (n = 22) and gamma or vitamins B in combination with glutaminic acid in the control group (n = 19). Cortexin used in the therapy of neurotoxic reactions produced a beneficial effect and permitted 90.9% of the patients to continue to use isoniazid while 42.2% of the controls resumed using isoniazid.
Lysov
A V
AV
Mordyk
A V
AV
Zatvornitskiĭ
V A
VA
Kondria
A V
AV
D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005971:Glutamates / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D036341:Intercellular Signaling Peptides and Proteins; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009422:Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology; D010455:Peptides / Q000627:therapeutic use; D012189:Retrospective Studies; D012800:Siberia / Q000453:epidemiology; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014803:Vitamin B Complex / Q000627:therapeutic use
D000995:Antitubercular Agents; D005971:Glutamates; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D014803:Vitamin B Complex; C056590:cortexin; D007538:Isoniazid